Last, in the human ocular disease setting, the correlation of SPP1 levels with the severity of optic neuropathy in patients with glaucoma raises the possibility that SPP1 may be a relevant biomarker and a potential therapeutic target for glaucoma. This evidence concerns the gene SPP1 and optic nerve disorder.